China Botanic Attends 67th PHARMCHINA Fair
HARBIN, China, May 17, 2012 /PRNewswire-Asia/ — China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines (“TCM”) in China, today announced that the Company recently attended and exhibited its anti-depressant products at the 67th PHARMCHINA fair (“the Fair”) recently held in Hefei, China.
China Botanic introduced the Company’s Siberian Ginseng (Acanthopanax) series products, Schisandra products, Tianma series products and other botanic based anti-depressant products at the Fair. Due to the increased recognition of China Botanic’s all-natural and plant based remedies, the Company has received several orders for its products with a total value of approximately RMB 5 million (or approximately $0.8 million).
“We feel delighted that our pharmaceutical products have received greater recognition at this year’s PHARMCHINA, which is China’s largest pharmaceutical fair,” commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. “We will continue to participate in similar public and industry events in the future to improve the market awareness of our brand and hope to generate more revenues for China Botanic.”
PHARMCHINA is the largest exhibition in China’s pharmaceutical industry. With a history of over 30 years, the PHARMCHINA fair covers an area of approximately 100,000 square meters, exhibits over 80,000 pharmaceutical products, and attracts over 3,500 exhibitors from more than 18 countries and regions. Twice a year, exhibitors and visitors attend PHARMCHINA for new business opportunities in the rapidly developing China’s pharmaceutical market, including chemical-based drugs, TCM, bio-pharmaceuticals, OTC medicine, health care products, cosmetics, and healthcare-related technologies and other services. For more information, please visit http://en.pharmchina.com.cn/.
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management’s beliefs, assumptions and expectations of the Company’s future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company’s ability to manage expansion of its operations effectively, and other factors detailed in the Company’s annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: email@example.com Email: firstname.lastname@example.org Website: www.ccgirasia.com
SOURCE China Botanic Pharmaceutical Inc.